Atopic Dermatitis

>

Latest News

Fall Clinical: Lebrikizumab-lbkz shows sustained skin clearance with one dose every 8 weeks | Image Credit: © arhat - © arhat - stock.adobe.com.
Fall Clinical: Lebrikizumab-lbkz shows sustained skin clearance with one dose every 8 weeks

October 24th 2025

A single injection once per 8 weeks vs once per 4 weeks demonstrated similar levles of skin clearance, for AD patients 12 years and older, according to a Fall Clinical announcement.

Fall Clinical: Roflumilast creams 0.15%, 0.05% reduce sleep disruptions in AD patients 2 years, older | Image Credit: © Gorodenkoff - © Gorodenkoff - stock.adobe.com.
Fall Clinical: Roflumilast creams 0.15%, 0.05% reduce sleep disruptions in AD patients 2 years, older

October 24th 2025

FDA approves roflumilast cream 0.05% for atopic dermatitis for children 2 to 5 years | Image credit: Contemporary Pediatrics
FDA approves roflumilast cream 0.05% for atopic dermatitis for children aged 2 to 5 years

October 6th 2025

5 pediatric FDA decisions to watch for in Q4 2025 | Image credit: Contemporary Pediatrics
Key pediatric FDA decisions to watch for in Q4 2025

September 30th 2025

Phase 2b study: Rezpegaldesleukin demonstrates efficacy in atopic dermatitis patients | Image Credit: © Марина Терехова - stock.adobe.com.
Phase 2b study: Rezpegaldesleukin demonstrates efficacy in atopic dermatitis patients

September 19th 2025

<123456
© 2025 MJH Life Sciences

All rights reserved.